Trial: 202105038

An open label, multi-center Phase IIIbstudy of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloidleukemia inchronic phase (CML-CP) with and without T315I mutation(AIM4CML)

Phase

III

Principal Investigator

Abboud, Camille

Disease Site

Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov